Injury to the blood-brain barrier (BBB) is a key feature of intracerebral hemorrhage (ICH) and may contribute to perihematomal cell injury. Pretreatment with the heme oxygenase (HO)-1 inducer hemin improves barrier function and neurological outcome in experimental models of traumatic and ischemic CNS injury. Since hemin is already in clinical use to treat acute porphyrias, this translational study was designed to test its effect on BBB function when initiated after ICH in two mouse models. At a dose similar to those used in most preconditioning studies (26 mg/kg i.p.), post-hemorrhage treatment with hemin reduced parenchymal extravasation of Evans blue by about three-quarters in both the blood injection and collagenase ICH models. Similar efficacy was observed when treatment was begun at 1 or 3 h. At the lower dose that is currently in clinical use (4 mg/kg beginning at 3 h), hemin also improved barrier function in both models, as assessed by both Evans blue and FITC-dextran leakage; however, it was somewhat less potent, reducing Evans blue leakage by about half. This dose was nevertheless sufficient to attenuate striatal cell loss and accelerate neurological recovery. Consistent with prior observations, striatal HO-1 expression was increased by hemin, and was localized to perivascular cells. These results suggest that hemin may be an effective therapy for ICH with a clinically relevant time window. Further study of the repurposing of this old drug seems warranted.
Introduction
Hemin, the ferric form of heme with a chloride ligand, accumulates in intracranial hematomas (Letarte et al., 1993) . It may contribute to cell injury in adjacent tissue by a direct cytotoxic effect and also by release of redox-active iron with its breakdown (Robinson et al., 2009) . However, at nontoxic concentrations, hemin delivers a potent preconditioning stimulus to cultured cells that protects them from subsequent exposure to toxic concentrations of hemin and other oxidants (Balla et al., 1992; Li et al., 2009; Regan et al., 2000) . This effect, which requires a preconditioning interval of several hours (Balla et al., 1993) , is mediated at least in part by induction of heme oxygenase (HO)-1 (Belcher et al., 2006; Li et al., 2009) . In vivo, systemic pretreatment with hemin was protective in multiple acute injury models, including brain (Takizawa et al., 1998; Zhang et al., 2008) , heart (Clark et al., 2000; Hangaishi et al., 2000) , kidney (Demirogullari et al., 2006) , liver (Xue et al., 2007) , and gut (Attuwaybi et al., 2004) ischemia/reperfusion, spinal cord trauma (Yamauchi et al., 2004) , colitis (Zhong et al., 2010) , and pancreatitis (Habtezion et al., 2011) . Hemin is excluded from most organs after parenteral injection due to rapid binding to hemopexin or albumin (Linden et al., 1987) , and its primary site of action appears to be the microvasculature (Belcher et al., 2006; Holzen et al., 2008; Lindenblatt et al., 2004) . In the CNS, this resulted in a significant attenuation of blood-spinal cord barrier permeability in a mouse weight-drop contusion model (Yamauchi et al., 2004) .
Hematin, which is ferric heme with a hydroxide ligand rather than chloride, is currently FDA-approved to treat neurovisceral symptoms associated with the acute porphyrias. A related compound, hemin arginate, is marketed for the same indication in Europe. Although the putative mechanism of action in these diseases is feedback inhibition of δ-aminolevulinic acid synthase rather than HO-1 induction (Anderson et al., 2005) , the safety of ferric heme has already been established by decades of clinical use. It is somewhat surprising, then, that the therapeutic potential of hemin or hematin postconditioning has not been addressed in translational studies to date. One possible explanation is an inadequate time window. Since hemin is not directly protective, but rather upregulates an endogenous defense against oxidative stress and inflammation, its onset of action is likely to be delayed for several hours. It therefore may not be an ideal agent for treating rapidly-progressing insults such as CNS ischemia or trauma.
Two factors suggest that parenteral hemin may be a particularly attractive drug therapy for intracerebral hemorrhage (ICH). First, the heme-mediated component of injury after ICH is delayed for at least 1-2 days in experimental models (Xi et al., 1998) , providing an adequate time window to manifest the protective effects of hemin conditioning. This delay represents the interval required for both
